The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease

[1]  J. Lazarus,et al.  A multi-society Delphi consensus statement on new fatty liver disease nomenclature. , 2023, Journal of hepatology.

[2]  V. Wong,et al.  A multi-society Delphi consensus statement on new fatty liver disease nomenclature. , 2023, Annals of hepatology.

[3]  S. Lipton,et al.  Apoptotic cell death in disease—Current understanding of the NCCD 2023 , 2023, Cell Death & Differentiation.

[4]  Michael Jew,et al.  Alcohol, the gut microbiome, and liver disease , 2023, Journal of gastroenterology and hepatology.

[5]  S. Sookoian,et al.  Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making , 2023, Expert review of gastroenterology & hepatology.

[6]  N. Waszkiewicz,et al.  Old and New Biomarkers of Alcohol Abuse: Narrative Review , 2023, Journal of clinical medicine.

[7]  Haihe Wang,et al.  Molecular mechanisms of autophagy and implications in liver diseases , 2023, Liver Research.

[8]  A. Vidal-Puig,et al.  An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. , 2023, Journal of hepatology.

[9]  A. Geerts,et al.  Meta‐analysis: The impact of light‐to‐moderate alcohol consumption on progressive non‐alcoholic fatty liver disease , 2023, Alimentary pharmacology & therapeutics.

[10]  J. Mellinger,et al.  The Changing Epidemiology of Alcohol-Associated Liver Disease: Gender, Race, and Risk Factors , 2022, Seminars in Liver Disease.

[11]  A. Eguchi,et al.  Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[12]  R. Loomba,et al.  Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD , 2022, Alimentary pharmacology & therapeutics.

[13]  Jianguo Wu,et al.  Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease , 2022, Annual review of pathology.

[14]  H. Cortez‐Pinto,et al.  Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors , 2022, Nature reviews. Gastroenterology & hepatology.

[15]  M. Roden,et al.  Mitochondrial alterations in fatty liver diseases. , 2022, Journal of hepatology.

[16]  V. Tremaroli,et al.  Microbiome-derived ethanol in nonalcoholic fatty liver disease , 2022, Nature Medicine.

[17]  H. El‐Serag,et al.  Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality , 2022, JAMA network open.

[18]  V. Männistö,et al.  Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. , 2022, Journal of hepatology.

[19]  N. Lanthier,et al.  Duodenal CD8+ T resident memory cell apoptosis contributes to gut barrier dysfunction and microbial translocation in early alcohol‐associated liver disease in humans , 2022, Alimentary pharmacology & therapeutics.

[20]  N. Syn,et al.  Hepatocellular Carcinoma Incidence in Alcohol-associated Cirrhosis: Systematic Review and Meta-analysis. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  L. Henry,et al.  Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world , 2022, Alimentary pharmacology & therapeutics.

[22]  Rakesh K. Arya,et al.  Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding , 2022, Hepatology.

[23]  Afroza Ferdouse,et al.  Pathogenesis of Alcohol-Associated Fatty Liver: Lessons From Transgenic Mice , 2022, Frontiers in Physiology.

[24]  R. D. de Knegt,et al.  Mafld and excessive alcohol consumption are both independent risk factors for mortality. , 2022, Hepatology.

[25]  K. Clément,et al.  Risk assessment with gut microbiome and metabolite markers in NAFLD development , 2022, Science Translational Medicine.

[26]  R. Schwabe,et al.  Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. , 2022, Journal of hepatology.

[27]  Jian-Min Yuan,et al.  NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population , 2022, Hepatology communications.

[28]  U. Huber-Schönauer,et al.  Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. , 2022, Journal of hepatology.

[29]  J. Bajaj,et al.  NATURAL HISTORY OF ALCOHOL-ASSOCIATED LIVER DISEASE: UNDERSTANDING THE CHANGING LANDSCAPE OF PATHOPHYSIOLOGY AND PATIENT CARE. , 2022, Gastroenterology.

[30]  J. Arab,et al.  Public Health Measures and Prevention of Alcohol-Associated Liver Disease. , 2022, Journal of clinical and experimental hepatology.

[31]  Huiping Zhou,et al.  Key Signaling in Alcohol-Associated Liver Disease: The Role of Bile Acids , 2022, Cells.

[32]  M. E. Shaker,et al.  The contribution of sterile inflammation to the fatty liver disease and the potential therapies. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[33]  V. Salomaa,et al.  Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting , 2022, Cell metabolism.

[34]  V. Shah,et al.  Epigenetics of alcohol-related liver diseases , 2022, JHEP reports : innovation in hepatology.

[35]  R. Bataller,et al.  Cigarette Smoking and Liver Diseases. , 2022, Journal of hepatology.

[36]  J. Rehm,et al.  Impact of introducing a minimum alcohol tax share in retail prices on alcohol-attributable mortality in the WHO European Region: A modelling study , 2022, The Lancet Regional Health - Europe.

[37]  Shelly C. Lu,et al.  Depletion of mitochondrial methionine adenosyltransferase α1 triggers mitochondrial dysfunction in alcohol-associated liver disease , 2022, Nature Communications.

[38]  J. Armendáriz-Borunda,et al.  An Update in Epigenetics in Metabolic-Associated Fatty Liver Disease , 2022, Frontiers in Medicine.

[39]  J. Beulens,et al.  Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context , 2022, Current Atherosclerosis Reports.

[40]  B. Hanratty,et al.  Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis , 2022, BMJ Open.

[41]  M. Knuiman,et al.  Alcohol Consumption and Cardiovascular Outcomes in Patients With Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study , 2021, Hepatology communications.

[42]  J Zhang,et al.  2019 global NAFLD prevalence - A systematic review and meta-analysis. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[43]  R. Malekzadeh,et al.  The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? , 2021, Journal of hepatology.

[44]  V. de Lédinghen,et al.  Long‐term prognosis of patients with alcohol‐related liver disease or non‐alcoholic fatty liver disease according to metabolic syndrome or alcohol use , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[45]  Bin Gao,et al.  Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis , 2021, Frontiers in Endocrinology.

[46]  D. Thabut,et al.  Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. , 2021, Journal of hepatology.

[47]  W. Kim,et al.  Research methodologies to address clinical unmet needs and challenges in alcohol‐associated liver disease , 2021, Hepatology.

[48]  P. Hayes,et al.  Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity , 2021, Hepatology.

[49]  Donghee Kim,et al.  Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. , 2021, Journal of hepatology.

[50]  R. Bataller,et al.  Super enhancer regulation of cytokine-induced chemokine production in alcoholic hepatitis , 2021, Nature Communications.

[51]  Dongqing Wu,et al.  Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease , 2021, Frontiers in Physiology.

[52]  P. Kamath,et al.  Alcohol‐associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics , 2021, Alimentary pharmacology & therapeutics.

[53]  A. Feldstein,et al.  Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity , 2021, Seminars in Liver Disease.

[54]  T. Suvitaival,et al.  Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication , 2021, JHEP reports : innovation in hepatology.

[55]  R. Bataller,et al.  Impact of Public Health Policies on Alcohol‐Associated Liver Disease in Latin America: An Ecological Multinational Study , 2021, Hepatology.

[56]  V. Salomaa,et al.  Alcohol Intake and Total Mortality in 142,960 Individuals from the MORGAM Project: a population-based study. , 2021, Addiction.

[57]  E. El-Omar,et al.  Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank , 2021, European Journal of Clinical Nutrition.

[58]  M. Nguyen,et al.  Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[59]  I. Amit,et al.  XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis , 2021, Nature Medicine.

[60]  J. Lazarus,et al.  NAFLD: Challenges and opportunities to address the public health challenge in Latin America. , 2021, Annals of hepatology.

[61]  S. Friedman,et al.  Mechanisms and disease consequences of nonalcoholic fatty liver disease , 2021, Cell.

[62]  M. Gage,et al.  Liver macrophages and inflammation in physiology and physiopathology of non‐alcoholic fatty liver disease , 2021, The FEBS journal.

[63]  E. Vittinghoff,et al.  Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: An individual patient data meta-analysis. , 2021, Alcoholism, clinical and experimental research.

[64]  Luca Valenti,et al.  Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets , 2021, JHEP reports : innovation in hepatology.

[65]  H. Tilg,et al.  Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH , 2021, Nature.

[66]  T. Ayer,et al.  Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-related Liver Disease: A Modelling Study , 2021, medRxiv.

[67]  C. Trautwein,et al.  An Experimental DUAL Model of Advanced Liver Damage , 2021, Hepatology communications.

[68]  T. Luedde,et al.  Diagnosis and management of secondary causes of steatohepatitis. , 2021, Journal of hepatology.

[69]  K. Faber,et al.  How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? , 2021, Hepatology International.

[70]  B. Staels,et al.  PPARs in liver physiology. , 2021, Biochimica et biophysica acta. Molecular basis of disease.

[71]  H. El‐Serag,et al.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.

[72]  B. Schnabl,et al.  Gut dysbiosis as a driver in alcohol-induced liver injury , 2020, JHEP reports : innovation in hepatology.

[73]  Mary E. Haas,et al.  Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study. , 2020, Gastroenterology.

[74]  C. Byrne,et al.  The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease , 2020, Clinical and molecular hepatology.

[75]  Y. Rotman,et al.  Immunological mechanisms and therapeutic targets of fatty liver diseases , 2020, Cellular & molecular immunology.

[76]  Layla Shojaie,et al.  Cell Death in Liver Diseases: A Review , 2020, International journal of molecular sciences.

[77]  J. Hampe,et al.  Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores , 2020, Journal of hepatology.

[78]  R. Xu,et al.  Neutrophils in liver diseases: pathogenesis and therapeutic targets , 2020, Cellular & Molecular Immunology.

[79]  D. Brenner,et al.  A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. , 2020, Cell Metabolism.

[80]  F. Tacke,et al.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors , 2020, Nature Reviews Gastroenterology & Hepatology.

[81]  F. Tacke,et al.  Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities , 2020, Cellular & molecular immunology.

[82]  P. Burra,et al.  NAFLD and liver transplantation: Disease burden, current management and future challenges , 2020, JHEP reports : innovation in hepatology.

[83]  K. Cusi,et al.  Latin American Association for the Study of the Liver (ALEH) Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. , 2020, Annals of hepatology.

[84]  T. Miyata,et al.  Programmed cell death in alcohol-associated liver disease , 2020, Clinical and molecular hepatology.

[85]  B. Gao,et al.  Obesity and binge alcohol intake are deadly combination to induce steatohepatitis: A model of high-fat diet and binge ethanol intake , 2020, Clinical and molecular hepatology.

[86]  J. Whitfield,et al.  Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. , 2020, The American journal of gastroenterology.

[87]  A. Sanyal,et al.  The times they are a-changin' (for NAFLD as well). , 2020, Journal of hepatology.

[88]  A. Kulkarni,et al.  Non-alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease: Two Intertwined Entities , 2020, Frontiers in Medicine.

[89]  Yongzhe Li,et al.  Genetic variant rs72613567 of HSD17B13 gene reduces alcohol‐related liver disease risk in Chinese Han population , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[90]  Nik Raihan Nik Mustapha,et al.  Modest alcohol intake not associated with significant hepatic steatosis or more severe liver disease among patients with diabetes mellitus , 2020, Journal of gastroenterology and hepatology.

[91]  Z. Goodman,et al.  From NAFLD to MAFLD: Implications of a Premature Change in Terminology , 2020, Hepatology.

[92]  F. Tacke,et al.  The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis , 2020, Seminars in Liver Disease.

[93]  M. Stepanova,et al.  Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[94]  F. Gonzalez,et al.  Nuclear receptors and non-alcoholic fatty liver disease: An update , 2020 .

[95]  S. Sookoian,et al.  Epigenetics factors in nonalcoholic fatty liver disease , 2020, Expert review of gastroenterology & hepatology.

[96]  C. Datz,et al.  Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers , 2020, Hepatology.

[97]  Suying Li,et al.  Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data , 2020, Alimentary pharmacology & therapeutics.

[98]  G. Gores,et al.  Lytic Cell Death in Metabolic Liver Disease. , 2020, Journal of hepatology.

[99]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[100]  A. Chowdhury,et al.  Epidemiology of non-alcoholic and alcoholic fatty liver diseases. , 2020, Translational gastroenterology and hepatology.

[101]  J. Banales,et al.  Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy , 2020, Cells.

[102]  J. Ludvigsson,et al.  Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients , 2020, Gut.

[103]  B. Nordestgaard,et al.  Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population , 2020, Hepatology.

[104]  I. Maričić,et al.  Differential activation of unconventional T cells, including iNKT cells, in alcohol-related liver disease. , 2020, Alcoholism, clinical and experimental research.

[105]  Luca Valenti,et al.  Update on NAFLD genetics: from new variants to the clinic. , 2020, Journal of hepatology.

[106]  S. Wild,et al.  Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis , 2019, Hepatology.

[107]  V. Salomaa,et al.  Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow‐Up of Population Cohorts , 2020, Hepatology.

[108]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[109]  R. Schwabe,et al.  Mechanisms of Fibrosis Development in NASH. , 2020, Gastroenterology.

[110]  G. Perlemuter,et al.  A Model to Identify Heavy Drinkers at High Risk for Liver Disease Progression. , 2020, Clinical Gastroenterology and Hepatology.

[111]  E. Benjamin,et al.  Alcohol Use is Associated with Hepatic Steatosis Among Persons with Presumed Non-alcoholic Fatty Liver Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[112]  C. Celsa,et al.  The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives , 2019, International journal of molecular sciences.

[113]  E. Albano,et al.  Adaptive immunity: an emerging player in the progression of NAFLD , 2019, Nature Reviews Gastroenterology & Hepatology.

[114]  R. Bataller,et al.  Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[115]  A. Gasbarrini,et al.  Cancer and Mediterranean Diet: A Review , 2019, Nutrients.

[116]  J. Rehm,et al.  Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. , 2019, The American journal of gastroenterology.

[117]  M. Arrese,et al.  Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations , 2019, Expert review of gastroenterology & hepatology.

[118]  V. Wong,et al.  Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[119]  Douglas A. Simonetto,et al.  Mechanical Stretch Increases Expression of CXCL1 in Liver Sinusoidal Endothelial Cells to Recruit Neutrophils, Generate Sinusoidal Microthombi, and Promote Portal Hypertension. , 2019, Gastroenterology.

[120]  Ning Wang,et al.  Recent Insights Into the Role of Immune Cells in Alcoholic Liver Disease , 2019, Front. Immunol..

[121]  Douglas A. Simonetto,et al.  Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH). , 2019, Annals of hepatology.

[122]  H. Tsukamoto,et al.  Inflammatory pathways in alcoholic steatohepatitis. , 2019, Journal of hepatology.

[123]  Yoosoo Chang,et al.  Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study , 2018, Hepatology.

[124]  V. de Lédinghen,et al.  Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. , 2018, Journal of hepatology.

[125]  T. Luedde,et al.  Apoptosis and necroptosis in the liver: a matter of life and death , 2018, Nature Reviews Gastroenterology & Hepatology.

[126]  B. Neuschwander‐Tetri,et al.  Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[127]  Xi C. He,et al.  Impaired TFEB-Mediated Lysosome Biogenesis and Autophagy Promote Chronic Ethanol-Induced Liver Injury and Steatosis in Mice. , 2018, Gastroenterology.

[128]  E. Paschetta,et al.  Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis. , 2018, Gastroenterology.

[129]  E. Tapper,et al.  Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study , 2018, British Medical Journal.

[130]  H. Cortez‐Pinto,et al.  EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. , 2018, Journal of hepatology.

[131]  J. Lykkesfeldt,et al.  Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease , 2018, Cellular and Molecular Life Sciences.

[132]  A. Jula,et al.  Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population , 2018, Hepatology.

[133]  A. Feldstein,et al.  Triggering and resolution of inflammation in NASH , 2018, Nature Reviews Gastroenterology & Hepatology.

[134]  T. Therneau,et al.  Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community study , 2018, Hepatology.

[135]  N. Tanaka,et al.  Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis , 2018, World journal of gastroenterology.

[136]  Lanman Xu,et al.  The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis , 2018, Expert review of gastroenterology & hepatology.

[137]  A. Andreasson,et al.  Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life. , 2018, Journal of hepatology.

[138]  A. McCullough,et al.  The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. , 2018, Clinics in liver disease.

[139]  G. Gores,et al.  Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation , 2018, Gut.

[140]  M. Trauner,et al.  Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. , 2018, Annual review of pathology.

[141]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[142]  Manuel Romero-Gómez,et al.  Treatment of NAFLD with diet, physical activity and exercise. , 2017, Journal of hepatology.

[143]  G. Gores,et al.  Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. , 2017, JCI insight.

[144]  N. Terrault,et al.  Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review , 2017, Hepatology.

[145]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[146]  Robert V Farese,et al.  Lipid droplets and liver disease: from basic biology to clinical implications , 2017, Nature Reviews Gastroenterology &Hepatology.

[147]  K. Hajifathalian,et al.  Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study , 2017, Hepatology.

[148]  R. Hultcrantz,et al.  Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease , 2017, Scandinavian journal of gastroenterology.

[149]  Pierre Bedossa,et al.  Pathology of non‐alcoholic fatty liver disease , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[150]  S. Sookoian,et al.  Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease , 2016, Alimentary pharmacology & therapeutics.

[151]  D. Mann,et al.  Epigenetics in liver disease: from biology to therapeutics , 2016, Gut.

[152]  R. Bataller,et al.  Biomarkers for monitoring alcohol use , 2016, Clinical liver disease.

[153]  P. Dawson,et al.  Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives , 2016, Hepatology.

[154]  L. Henry,et al.  Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. , 2016, Gastroenterology.

[155]  J. Bajaj,et al.  Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? , 2016, Gastroenterology.

[156]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[157]  Yoshiyuki Suzuki,et al.  Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[158]  A. Feldstein,et al.  Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. , 2016, Journal of Hepatology.

[159]  Chih-Hao Chang,et al.  Superoxide Dismutase 2 Genetic Variation as a Susceptibility Risk Factor for Alcoholic Cirrhosis. , 2016, Alcohol and alcoholism.

[160]  Alexis M. Kalergis,et al.  Innate Immunity and Inflammation in NAFLD/NASH , 2016, Digestive Diseases and Sciences.

[161]  H. Hermanns,et al.  Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. , 2015, Cytokine & growth factor reviews.

[162]  K. Huse,et al.  A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis , 2015, Nature Genetics.

[163]  G. Szabo,et al.  Inflammasome activation in the liver: Focus on alcoholic and non-alcoholic steatohepatitis. , 2015, Clinics and research in hepatology and gastroenterology.

[164]  D. Mashek,et al.  Hepatic lipid droplet biology: Getting to the root of fatty liver , 2015, Hepatology.

[165]  Y. Kuo,et al.  PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease , 2015, The American Journal of Gastroenterology.

[166]  C. Trautwein,et al.  TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess. , 2015, Journal of hepatology.

[167]  Kazuhide Yamamoto,et al.  Roles of alcohol consumption in fatty liver: a longitudinal study. , 2015, Journal of hepatology.

[168]  P. Dawson,et al.  Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids , 2015, Acta pharmaceutica Sinica. B.

[169]  G. Gores,et al.  Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis , 2014, Cellular and molecular gastroenterology and hepatology.

[170]  C. la Vecchia,et al.  Alcohol consumption and site-specific cancer risk: a comprehensive dose–response meta-analysis , 2014, British Journal of Cancer.

[171]  Sébastien Matamoros,et al.  Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity , 2014, Proceedings of the National Academy of Sciences.

[172]  L. Bolondi,et al.  Significance of serum and hepatic microRNA‐122 levels in patients with non‐alcoholic fatty liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[173]  K. Clément,et al.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease , 2014, Nature Communications.

[174]  G. Szabo,et al.  Acute Binge Drinking Increases Serum Endotoxin and Bacterial DNA Levels in Healthy Individuals , 2014, PloS one.

[175]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[176]  H. Conjeevaram,et al.  Effect of lifetime alcohol consumption on the histological severity of non‐alcoholic fatty liver disease , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[177]  S. Sookoian,et al.  Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals , 2013, Gut.

[178]  G. Szabo,et al.  MicroRNAs in liver disease , 2013, Nature Reviews Gastroenterology &Hepatology.

[179]  G. Szabo,et al.  Immune and inflammatory pathways in NASH , 2013, Hepatology International.

[180]  C. Trautwein,et al.  Hepatocyte caspase‐8 is an essential modulator of steatohepatitis in rodents , 2013, Hepatology.

[181]  Chien-Jen Chen,et al.  Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. , 2013, American journal of epidemiology.

[182]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[183]  A. Sanyal,et al.  Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). , 2012, Journal of hepatology.

[184]  T. Roskams,et al.  EASL clinical practical guidelines: management of alcoholic liver disease. , 2012, Journal of hepatology.

[185]  J. Olefsky,et al.  Neutrophils mediate insulin resistance in high fat diet fed mice via secreted elastase , 2012, Nature Medicine.

[186]  H. Rangwala,et al.  Colonic microbiome is altered in alcoholism. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[187]  L. N. Valenti,et al.  Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms , 2012, Hepatology.

[188]  L. Valenti,et al.  The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. , 2012, Journal of hepatology.

[189]  M. Fukui,et al.  Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. , 2012, World journal of gastroenterology.

[190]  A. Lugea,et al.  Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. , 2011, Journal of hepatology.

[191]  Vincent Wai-Sun Wong,et al.  Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography , 2011, Gut.

[192]  C. Hellerbrand,et al.  A new model of interactive effects of alcohol and high-fat diet on hepatic fibrosis. , 2011, Alcoholism, clinical and experimental research.

[193]  A. Ido,et al.  Alcohol drinking patterns and the risk of fatty liver in Japanese men , 2011, Journal of Gastroenterology.

[194]  F. Ikeda,et al.  Alcohol consumption appears to protect against non‐alcoholic fatty liver disease , 2011, Alimentary pharmacology & therapeutics.

[195]  J. Rehm,et al.  Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. , 2010, Drug and alcohol review.

[196]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[197]  George Davey Smith,et al.  Supplementary Table S1 , 2008 .

[198]  A. McCullough,et al.  Alcoholic Liver Disease , 2010, The American Journal of Gastroenterology.

[199]  Hajime Sato,et al.  Light and Moderate Alcohol Consumption Significantly Reduces the Prevalence of Fatty Liver in the Japanese Male Population , 2009, The American Journal of Gastroenterology.

[200]  M. Holmqvist,et al.  Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease , 2009, Scandinavian journal of gastroenterology.

[201]  R. Xu,et al.  Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease , 2008, Hepatology.

[202]  C. Shin,et al.  Prospective study of alcohol consumption and metabolic syndrome. , 2008, The American journal of clinical nutrition.

[203]  G. Bedogni,et al.  Incidence and natural course of fatty liver in the general population: The Dionysos study , 2007, Hepatology.

[204]  S. Sanderson,et al.  Utility of a new model to diagnose an alcohol basis for steatohepatitis. , 2006, Gastroenterology.

[205]  G. Gores,et al.  Apoptosis in alcoholic and nonalcoholic steatohepatitis. , 2005, Frontiers in bioscience : a journal and virtual library.

[206]  J. Reddy,et al.  Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. , 2003, Current molecular medicine.

[207]  P. Bedossa,et al.  Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.

[208]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[209]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.

[210]  G. Brandi,et al.  Drinking habits as cofactors of risk for alcohol induced liver damage , 1997, Gut.

[211]  F. Capron,et al.  Excess weight risk factor for alcoholic liver disease , 1997, Hepatology.

[212]  T. Sørensen,et al.  Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study , 1996, Hepatology.

[213]  R. Loomba,et al.  Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[214]  G. Garas,et al.  Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non‐alcoholic Fatty Liver Disease , 2018, American Journal of Gastroenterology.

[215]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[216]  T. Joh,et al.  Alcohol Drinking May Not Be a Major Risk Factor for Fatty Liver in Japanese Undergoing a Health Checkup , 2008, Digestive Diseases and Sciences.